Evidence map›Paper›PMID 31892271›Full record

ArticleInternational journal of molecular sciences2019

Design, Synthesis and Molecular Modeling Study of Conjugates of ADP and Morpholino Nucleosides as A Novel Class of Inhibitors of PARP-1, PARP-2 and PARP-3.

Yuliya V Sherstyuk, Nikita V Ivanisenko, Alexandra L Zakharenko, Maria V Sukhanova, Roman Y Peshkov, Ilia V Eltsov, Mikhail M Kutuzov, Tatjana A Kurgina, Ekaterina A Belousova, Vladimir A Ivanisenko and 3 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Inhibition of DNA Repair Enzymes as a Valuable Pharmaceutical Approach.International journal of molecular sciences · 2023
    Article
  3. Design of the NewMolecules (Basel, Switzerland) · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Yuliya V SherstyukInstitute of Chemical Biology and Fundamental Medicine SB RAS, Lavrent'ev Ave, 8, 630090 Novosibirsk, Russia.
Nikita V IvanisenkoFederal Research Centre, Institute of Cytology and Genetics SB RAS, Lavrent'ev Ave, 10, 630090 Novosibirsk, Russia.
Alexandra L ZakharenkoInstitute of Chemical Biology and Fundamental Medicine SB RAS, Lavrent'ev Ave, 8, 630090 Novosibirsk, Russia.
Maria V SukhanovaInstitute of Chemical Biology and Fundamental Medicine SB RAS, Lavrent'ev Ave, 8, 630090 Novosibirsk, Russia.
Roman Y PeshkovNovosibirsk State University, Pirogova St., 2, 630090 Novosibirsk, Russia.
Ilia V EltsovNovosibirsk State University, Pirogova St., 2, 630090 Novosibirsk, Russia.
Mikhail M KutuzovInstitute of Chemical Biology and Fundamental Medicine SB RAS, Lavrent'ev Ave, 8, 630090 Novosibirsk, Russia.
Tatjana A KurginaInstitute of Chemical Biology and Fundamental Medicine SB RAS, Lavrent'ev Ave, 8, 630090 Novosibirsk, Russia.
Ekaterina A BelousovaInstitute of Chemical Biology and Fundamental Medicine SB RAS, Lavrent'ev Ave, 8, 630090 Novosibirsk, Russia.
Vladimir A IvanisenkoFederal Research Centre, Institute of Cytology and Genetics SB RAS, Lavrent'ev Ave, 10, 630090 Novosibirsk, Russia.
Olga I LavrikInstitute of Chemical Biology and Fundamental Medicine SB RAS, Lavrent'ev Ave, 8, 630090 Novosibirsk, Russia.
Vladimir N SilnikovInstitute of Chemical Biology and Fundamental Medicine SB RAS, Lavrent'ev Ave, 8, 630090 Novosibirsk, Russia.
Tatyana V AbramovaInstitute of Chemical Biology and Fundamental Medicine SB RAS, Lavrent'ev Ave, 8, 630090 Novosibirsk, Russia.
Institute of Chemical Biology and Fundamental Medicine · RUInstitute of Cytology and Genetics · RUNovosibirsk State University · RU

Funding

Russian Science Foundation 17-74-20075Russian State funded budget projects АААА-А17-117020210022-4Российский Фонд Фундаментальных Исследований (РФФИ) 17-00-00097Российский Фонд Фундаментальных Исследований (РФФИ) 18-04-00352
6 · The paper itself

Abstract

We report on the design, synthesis and molecular modeling study of conjugates of adenosine diphosphate (ADP) and morpholino nucleosides as potential selective inhibitors of poly(ADP-ribose)polymerases-1, 2 and 3. Sixteen dinucleoside pyrophosphates containing natural heterocyclic bases as well as 5-haloganeted pyrimidines, and mimicking a main substrate of these enzymes, nicotinamide adenine dinucleotide (NAD+)-molecule, have been synthesized in a high yield. Morpholino nucleosides have been tethered to the β-phosphate of ADP via a phosphoester or phosphoramide bond. Screening of the inhibiting properties of these derivatives on the autopoly(ADP-ribosyl)ation of PARP-1 and PARP-2 has shown that the effect depends upon the type of nucleobase as well as on the linkage between ADP and morpholino nucleoside. The 5-iodination of uracil and the introduction of the P-N bond in NAD+-mimetics have shown to increase inhibition properties. Structural modeling suggested that the P-N bond can stabilize the pyrophosphate group in active conformation due to the formation of an intramolecular hydrogen bond. The most active NAD+ analog against PARP-1 contained 5-iodouracil 2'-aminomethylmorpholino nucleoside with IC50 126 ± 6 μM, while in the case of PARP-2 it was adenine 2'-aminomethylmorpholino nucleoside (IC50 63 ± 10 μM). In silico analysis revealed that thymine and uracil-based NAD+ analogs were recognized as the NAD+-analog that targets the nicotinamide binding site. On the contrary, the adenine 2'-aminomethylmorpholino nucleoside-based NAD+ analogs were predicted to identify as PAR-analogs that target the acceptor binding site of PARP-2, representing a novel molecular mechanism for selective PARP inhibition. This discovery opens a new avenue for the rational design of PARP-1/2 specific inhibitors.

Indexed as

Adenosine DiphosphateBinding SitesHumansMorpholinosNADNiacinamideNucleosidesPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesAdenosine DiphosphateMorpholinosNADNiacinamideNucleosidesPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesDNA repairmolecular modelingmorpholino nucleosidesNAD+ analogsPARP

Identifiers

PMID31892271
PMCPMC6982223
OpenAlexW2998725049

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.